Bosentan - Actelion

Drug Profile

Bosentan - Actelion

Alternative Names: Bosentan monohydrate; RO-470203; RO-470203-029; Tracleer

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Actelion Pharmaceuticals; Erasmus MC
  • Class Antihypertensives; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Skin ulcer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Skin ulcer
  • Phase II Behcet's syndrome
  • No development reported Diabetic foot ulcer
  • Discontinued Asthma; Heart failure; Inflammatory bowel diseases; Ischaemic heart disorders; Kidney disorders; Malignant melanoma; Myocardial infarction; Pulmonary fibrosis; Reperfusion injury; Transplant rejection

Most Recent Events

  • 06 Sep 2017 Registered for Pulmonary arterial hypertension (In children, In adolescents) (32mg) in USA (PO)
  • 06 Sep 2017 Actelion expects to make the 32mg dosage option of bosentan (Tracleer®) available in USA by the fourth quarter of 2017
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top